EuroPCR 2026: another extremely successful edition for CID!
During the attendance to the most important European congress in Interventional Cardiology, CID has decided to spotlight the “Remaining Challenges and Role of Innovative DES technology in complex PCI”, as the title of the sponsored symposium has indicated. The latest DES technologies brought on the market, in fact, provide good clinical outcome in easy/medium complex PCI, but when physicians face real challenging lesions and patients then not all DES platforms perform the same.
This important “physician and patient driven approach to PCI” has been exploited Wednesday May 20th, during the CID scientific session, in which 3 complex and challenging cases have helped to highlight those settings where the unique features of Cre8 EVO™ Amphilimus™ eluting DES provide superior clinical outcomes.
In the first PCI, Dr. Salvatore Colangelo has shown a case where the use of Guiding Extension Catheter (GEC) was needed to complete the procedure. During the presentation he has released for the first time ever the 1year clinical data of the DESIGNATE study, an independent multicentre registry of almost 700 consecutive PCIs that have required the use of a GEC. The study results have proven that the use of the polymer-free and abluminal reservoir based Cre8 EVO™ DES provides superior clinical outcome vs. all the latest surfaced coated durable or absorbable polymeric DES (TLF at 1year: 1.1% Cre8 EVO™ vs. 8.1% Other DES; p=0.021). The Abluminal Reservoir Technology plays a key “protecting role” in avoiding that the friction between outer DES surface and the inner GEC lumen reduces DES performance. These results confirm those single center data presented last year at EuroPCR2025 and published immediately after.
In the second, PCI Prof. Lim Soo Teik has presented a complex LM bifurcation case that has required a “double-kissing culotte” to be successfully treated. Also in this case, Cre8 EVO™ unique platform (no stent foreshortening/ Pt markers at stent ends/ “rectangular” cell geometry for easy crossing/ wide expansion range) combined with an optimal lesion preparation and intravascular imaging guidance has brought to a superb result.
In the last PCI, Dr. Rafael Romaguera has presented a case related to a diabetic patient with serious HBR comorbidities. In this patient he has highlighted how the un-matched Cre8 EVO™ efficacy in DM patients (as already proven in the SUGAR RCT 5years clinical results released during the LBT at CRT2026 earlier this year) is coupled improved safety, so important for this type of patients. In fact, being TLR statistically reduced in case of Cre8 EVO™ implantation, the lower risk of reintervention implies lower risk of DAPT restart with a consequent minor bleeding risk. Efficacy & safety are interconnected for all those patients - specifically the diabetic ones - who are also meeting the HBR criteria.
Please refer to the below link to review the full session:
https://www.youtube.com/watch?v=-tdtefx-AnA&t=3109s
